In the news release, TrialSpark announces addition of key strategic advisor Steve Holtzman, issued 20-Apr-2021 by TrialSpark over PR Newswire, we are advised by the company that the content has been updated. The complete, updated release follows:
TrialSpark appoints Steven Holtzman as Sr. Advisor to the company
Steven Holtzman will advise the company on how to accelerate its strategic, operational, and BD&L efforts as a drug development company with faster and more efficient clinical trial capabilities
NEW YORK, April 20, 2021 /PRNewswire/ -- TrialSpark Inc., a tech-enabled drug development company dedicated to improving the speed, quality, and innovation within clinical trials, announced the addition of life sciences veteran Steven Holtzman as Sr. Advisor to the company.
Steve is the former CEO of Decibel Therapeutics, EVP of Corporate Development of Biogen, Founder and CEO of Infinity Pharmaceuticals, CBO of Millennium Pharmaceuticals, and Founder and President of DNX BioTherapeutics. Steve joins TrialSpark to support the company as it builds its therapeutics pipeline, deepening its bench of drug development expertise. He will advise on corporate strategy, as TrialSpark builds a new kind of pharma and drug development company with a competitive advantage around faster and more innovative clinical trials.
"Every second in clinical development is crucial, but in the last few decades, nothing has materially changed in the way we conduct clinical trials. For many programs, the cost and time of a clinical trial still remains a major bottleneck in bringing new treatments to patients. I've known Ben and the TrialSpark team for several years and have been impressed with their technology-first approach to trials and the opportunity to transform the efficiency and quality of drug development. I'm excited to become more formally involved with TrialSpark." - Steve Holtzman
"We're beyond excited to work together with Steve to advance our therapeutics pipeline and expand our suite of partnerships as we build a new kind of drug development company." - Benjamine Liu, co-founder and CEO, TrialSpark
TrialSpark has significantly improved the overall speed of trial execution for sponsors. Through a combination of digital and clinical improvements, TrialSpark reduces inefficiencies by improving time to execute site startup, EDC/ePRO development, patient recruitment, data capture, and site closeout. In a recent Phase II study, TrialSpark was able to complete study startup activities in under 10 weeks and complete enrollment and randomization >2X faster than industry comparators.
TrialSpark is also leveraging its own trial engine to build out a therapeutics pipeline of drugs through in-licensing or bespoke partnerships. For in-licensed or partnered drugs, TrialSpark leverages its unique capabilities to run the trials faster and more cost-effectively to unlock more value for its partners. If you are interested in partnering on a 2021 study or a longer term drug development partnership with TrialSpark, please direct your inquiries to [email protected].
TrialSpark is a technology company that runs end-to-end clinical trials. TrialSpark has built a technology platform that optimizes all aspects of a clinical trial, enabling faster trial completion, higher data quality, and a more efficient experience for all stakeholders. TrialSpark is building its own pipeline of early stage clinical assets through acquisitions, in-licensing agreements, and the creation of unique corporate structures. TrialSpark is backed by leading investors such as Michael Moritz, John Doerr, Sam Altman, Sequoia Capital, Thrive Capital, Casdin Capital, and Section 32.
Contact: [email protected]